US DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, Human DNA Vaccine) By Technology (Plasmid DNA Vaccine and Plasmid DNA Delivery) By Application (Oncology, Infectious Disease, and Others) Forecast period (2019-2025).
The US DNA Vaccine market is anticipated to grow at a CAGR 42.9% during the forecast period. The factors affecting the growth of DNA vaccination in the US include R&D funding, high healthcare expenditure, presence of key players and rising prevalence of cancer patients. A significant rise in R&D funding has witnessed in the past few years. For example, In April 2018, Inovio Pharmaceuticals Inc., a US firm has awarded approximately $56 million from CEPI (the Coalition for Epidemic Preparedness Innovations) for the development of DNA vaccines against MERS (Middle East Respiratory Syndrome) and Lassa fever. In addition, increasing poultry production in the country is also a major contributing factor for DNA vaccination in the US. According to the Poultry world, In the US, poultry production is set to an all-time high. It is expected to rise 3% annually from 2019 to 2021.
The US DNA vaccine is further segmented into type, technology, and application. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery. Based on application, the market is segmented into oncology, infectious disease and others. The US poultry farms such as Tyson Foods and Costo Poultry farm are planning to raise chicken production. Since 1993, Sanderson Farms has added seven plants. Costco’s $300 million plants in Nebraska are expected to produce nearly 100 million chickens in a year, while open in April 2019.
The key market player that are active in the market includes Arbutus Biopharma Corp., Dendreon Pharmaceuticals LLC, GE Healthcare, GlaxoSmithKline PLC., Green Cross Corp., Innovio Biomedical Corp., Immunomic Therapeutics, Merck & Co., Pfizer Inc., Protein Sciences Corp., Qed Biosciences Inc., Sanofi Inc., Tolerion Inc., Vical Inc. and Zoetis Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the US DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. The US DNA Vaccine Market Research and Analysis by Type
2. The US DNA Vaccine Market Research and Analysis by Technology
3. The US DNA Vaccine Market Research and Analysis by Application
The Report Covers:
The US DNA Vaccine market is anticipated to grow at a CAGR 42.9% during the forecast period. The factors affecting the growth of DNA vaccination in the US include R&D funding, high healthcare expenditure, presence of key players and rising prevalence of cancer patients. A significant rise in R&D funding has witnessed in the past few years. For example, In April 2018, Inovio Pharmaceuticals Inc., a US firm has awarded approximately $56 million from CEPI (the Coalition for Epidemic Preparedness Innovations) for the development of DNA vaccines against MERS (Middle East Respiratory Syndrome) and Lassa fever. In addition, increasing poultry production in the country is also a major contributing factor for DNA vaccination in the US. According to the Poultry world, In the US, poultry production is set to an all-time high. It is expected to rise 3% annually from 2019 to 2021.
The US DNA vaccine is further segmented into type, technology, and application. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery. Based on application, the market is segmented into oncology, infectious disease and others. The US poultry farms such as Tyson Foods and Costo Poultry farm are planning to raise chicken production. Since 1993, Sanderson Farms has added seven plants. Costco’s $300 million plants in Nebraska are expected to produce nearly 100 million chickens in a year, while open in April 2019.
The key market player that are active in the market includes Arbutus Biopharma Corp., Dendreon Pharmaceuticals LLC, GE Healthcare, GlaxoSmithKline PLC., Green Cross Corp., Innovio Biomedical Corp., Immunomic Therapeutics, Merck & Co., Pfizer Inc., Protein Sciences Corp., Qed Biosciences Inc., Sanofi Inc., Tolerion Inc., Vical Inc. and Zoetis Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the US DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. The US DNA Vaccine Market Research and Analysis by Type
2. The US DNA Vaccine Market Research and Analysis by Technology
3. The US DNA Vaccine Market Research and Analysis by Application
The Report Covers:
- Comprehensive Research Methodology of the US DNA Vaccine market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the US DNA Vaccine market.
- Insights about market determinants which are stimulating the US DNA Vaccine market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Arbutus Biopharma Corp.
- Dendreon Pharmaceuticals LLC
- GE Healthcare
- Glaxosmithkline PLC.
- Green Cross Corp.
- Immunomic Therapeutics
- Innovio Biomedical Corp.
- Merck & Co.
- Pfizer Inc.
- Protein Sciences Corp.
- Qed Biosciences Inc.
- Sanofi Inc.
- Tolerion Inc.
- Vical Inc.
- Zoetis Inc.
